Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Arsenic Trioxide Plus Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma

Study:

Phase I Study of Combined Radiotherapy and Arsenic Trioxide for the Treatment of Newly Diagnosed Malignant Glioma

Rationale:

Drugs such as arsenic trioxide may stop the growth of malignant glioma by stopping blood flow to the tumor. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining arsenic trioxide with radiation therapy may kill more tumor cells.

Purpose:

This phase I trial is studying the side effects and best dose of arsenic trioxide and radiation therapy in treating patients with newly diagnosed malignant glioma.

Study Status: Completed

Recruiting:
n/a

Condition Intervention Phase
Brain and Central Nervous System Tumors Drug: arsenic trioxide
Radiation: radiation therapy
Phase 1

Verified by Sidney Kimmel Comprehensive Cancer Center October, 2010

Sponsored by: Sidney Kimmel Comprehensive Cancer Center
Information provided by: Sidney Kimmel Comprehensive Cancer Center
ClinicalTrials.gov identifier: NCT00045565

Study Type: Interventional

Study Design: Primary Purpose: Treatment

Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195
United States

Samuel Ryu, MD., Study Chair

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site